Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/25024
DC FieldValueLanguage
dc.contributor.authorIljovska, Marinaen_US
dc.contributor.authorLazareva, Emilijaen_US
dc.contributor.authorSmichkoska, Snezhanaen_US
dc.contributor.authorKlisarovska, Violetaen_US
dc.contributor.authorStojkovski, Igoren_US
dc.contributor.authorPetkovska, Gordanaen_US
dc.contributor.authorMitreski, Nenaden_US
dc.date.accessioned2022-12-19T13:23:28Z-
dc.date.available2022-12-19T13:23:28Z-
dc.date.issued2022-12-16-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/25024-
dc.description.abstractIntroduction/Objective. This study aims to investigate the cardiotoxicity of long-term therapy with trastuzumab in patients with HER2 positive metastatic breast cancer. Methods. A total of 48 patients with metastatic HER2 positive breast cancer were analyzed. The patients received long-term trastuzumab (time of application was longer than 20 months). The analyzed characteristics of the patients were: age, initial stage of the disease, application of anti-HER2 therapy and anthracyclines in the adjuvant setting, the number and type of applied systemic therapies concomitant with trastuzumab in the metastatic setting. Cardiac toxicity was assessed using left ventricular ejection fraction (LVEF) values at three time points: at the beginning, in the middle, and at the end of treatment period for each patient separately. Results. In 17 (35.4%) patients the trastuzumab treatment was temporary discontinued. The average time of trastuzumab therapy interval was 52.2 ? 23.5 months. The mean LVEF values were 66.73 ? 7.02%, 64.62 ? 5.7% and 63.44 ? 6.1%, respectively. The mean values of LVEF differed significantly in the observed three time points (F=4.9 p=0.009). Post hoc pairwise comparison, using Bonferonni correction, confirmed significantly lower mean LVEF values at the end point (at the end of treatment) compared with the mean LVEF values at the beginning of anti-HER2 treatment (p = 0.019), but within the reference range of LVEF ?50%. Conclusion. The data confirm good safety profile of long-term trastuzumab therapy in HER2 positive metastatic breast cancer patients considering cardiotoxicity.en_US
dc.language.isoenen_US
dc.publisherNational Library of Serbiaen_US
dc.relation.ispartofSrpski arhiv za celokupno lekarstvoen_US
dc.subjectbreast canceren_US
dc.subjectcardiotoxicityen_US
dc.subjectejection fractionen_US
dc.subjecttrastuzumaben_US
dc.titleReal-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast canceren_US
dc.typeArticleen_US
dc.identifier.doi10.2298/sarh220308113i-
dc.identifier.issue00-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File Опис SizeFormat 
113-87-22-OLFv1.pdffull text492.6 kBAdobe PDFView/Open
Прикажи едноставен запис

Page view(s)

136
checked on 4.5.2025

Download(s)

41
checked on 4.5.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.